What is Quthero?
Quthero is a biotechnology firm dedicated to revolutionizing wound management through its patented platform technology. The company focuses on active, rapid, and healthy wound restoration, addressing a wide spectrum of clinical needs ranging from cosmetic and surgical wounds to burns and chronic ulcers. By enabling full epithelial restoration, Quthero aims to minimize scarring and reduce the systemic risks associated with slow healing, such as infection, pain, and long-term complications. Its flagship product, a single-application gel, represents a paradigm shift in therapeutic wound care, moving the industry away from traditional, passive dressing modalities toward a more efficient, biologically active treatment model.
How much funding has Quthero raised?
Quthero has raised a total of $517K across 2 funding rounds:
Debt
$17K
Other Financing Round
$500K
Debt (2021): $17K with participation from PPP
Other Financing Round (2024): $500K led by Ontario Centre of Innovation
Key Investors in Quthero
Ontario Centre of Innovation
A government-funded organization that drives the commercialization of cutting-edge research and fosters the development of next-generation innovators across Ontario's key economic sectors.
PPP
Public-Private Partnership
What's next for Quthero?
With the recent capital secured, Quthero is poised to advance its clinical development pipeline and expand its operational footprint. The strategic focus will likely center on scaling the manufacturing of its wound management gel and navigating the regulatory pathways required for broader commercial adoption. By leveraging its unique technology, the company is well-positioned to disrupt the multi-billion dollar wound care market, potentially setting a new standard for patient outcomes in both surgical and chronic care settings. Future milestones will likely involve expanding clinical trials and establishing key partnerships with healthcare providers to integrate its solution into standard clinical workflows.
See full Quthero company page
